Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Recombinant human luteinising hormone (rLH)

Lutropin alfa

Brand names: Luveris

A recombinant human luteinising hormone used with follicle-stimulating hormone to stimulate follicular development in selected women with severe gonadotrophin deficiency undergoing assisted reproduction.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It replicates the action of endogenous luteinising hormone on ovarian theca and granulosa cells, supporting follicular maturation and oestrogen production.

Prescribing in practice

  • Use only under specialist fertility supervision with ovarian ultrasound and hormone monitoring, because overstimulation can cause ovarian hyperstimulation syndrome and multiple pregnancy.
  • It is intended for co-administration with follicle-stimulating hormone in women with marked LH and FSH deficiency.
  • Exclude causes in which ovarian stimulation is inappropriate, such as uncontrolled endocrine disorders or hormone-dependent tumours, before treatment.

Monitoring

Monitor ovarian response with serial ultrasound and oestradiol measurement to guide dosing and reduce hyperstimulation and multiple-pregnancy risk.

Counselling the patient

  • Report abdominal pain, bloating, nausea or reduced urine output, which may signal ovarian hyperstimulation.
  • Understand that fertility treatment carries an increased chance of multiple pregnancy.
  • Attend all scan and blood-test appointments so treatment can be adjusted.

Evidence & guidelines

Recombinant luteinising hormone supports follicular development when combined with FSH in hypogonadotrophic hypogonadism, as reflected in assisted-reproduction practice and the SPC.

Reference: NICE CG156; HFEA; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways